Satellos Bioscience Inc. Common Stock (MSLE) — Cash Flow-to-Debt Ratio
Satellos Bioscience Inc. Common Stock (MSLE) has a Cash Flow-to-Debt Ratio of -1.77x as of December 2025, meaning its operating cash flow of $-7.26 Million could theoretically repay -2% of its total liabilities ($4.11 Million) in one year. See how liquid is Satellos Bioscience Inc. Common Stock's working capital to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Satellos Bioscience Inc. Common Stock Cash Flow-to-Debt Ratio (2021–2025)
Historical debt coverage capacity for Satellos Bioscience Inc. Common Stock across 5 annual periods. Also explore MSLE net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Satellos Bioscience Inc. Common Stock (2021–2025)
Year-by-year debt coverage analysis for Satellos Bioscience Inc. Common Stock. For market capitalisation and broader financial context, see Satellos Bioscience Inc. Common Stock stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -5.75x | $-23.60 Million | $4.11 Million | ▼ -18.6% |
| 2024 | -4.84x | $-17.40 Million | $3.59 Million | ▼ -51.6% |
| 2023 | -3.20x | $-8.73 Million | $2.73 Million | ▼ -56.4% |
| 2022 | -2.04x | $-4.26 Million | $2.09 Million | ▲ +14.6% |
| 2021 | -2.39x | $-3.95 Million | $1.65 Million | — |